Clinical Application Value Of EBUS-TBNA Needles in Lung Cancer Mediastinal Lymph Node Staging And Diagnosis Of Thoracic Diseases

https://profed.olympuschina.com/gs/thoracicsurgery/12628/

Since its introduction into clinical practice in the early 21st century, Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) has rapidly become one of the most revolutionary diagnostic technologies in the field of interventional pulmonology. The EBUS-TBNA needle, as the core consumable that directly contacts the lesion and acquires tissue, holds clinical value that extends beyond merely "getting in"-it lies in "precision targeting, adequate sampling, and definitive diagnosis." In lung cancer mediastinal lymph node staging (N staging), EBUS-TBNA has been recommended by NCCN, ACCP, and Chinese Lung Cancer Guidelines as a first-line invasive diagnostic modality, potentially replacing traditional mediastinoscopy in select cases. Clinical studies indicate that EBUS-TBNA achieves a diagnostic sensitivity of 83%–93% and a specificity approaching 100% for malignant mediastinal lymph nodes, performing particularly well in N2/N3 staging for lung adenocarcinoma, squamous cell carcinoma, and small cell lung cancer.

EBUS-TBNA needles are typically 21G, 22G, or 19G hollow-bore needles inserted through the working channel of a bronchoscope (mostly 2.2 mm). Under real-time convex probe ultrasound imaging, they penetrate the tracheal/bronchial wall to access paratracheal, subcarinal (station 7), para-aortic (stations 5/6), and hilar (stations 10/11) lymph nodes or mediastinal masses. Compared to conventional "blind" TBNA, real-time two-dimensional ultrasound allows operators to clearly delineate target size, borders, echotexture, and adjacent vasculature (via Color Doppler), significantly reducing the risk of vascular injury and increasing the first-pass positivity rate.

Different anatomical sites impose varying requirements on needle selection. For instance, accessing station 4L-often obstructed by the aortic arch requiring significant bronchoscope deflection-benefits from a 19G Nitinol (nickel-titanium alloy) flexible needle due to its superelasticity and superior compliance. Conversely, smaller right paratracheal nodes (e.g., 2R, 4R) are frequently sampled with a 22G fine needle to minimize airway wall trauma. Standard practice involves a "triple-pass" or "quadruple-pass" technique combined with negative pressure suction (-20 to -50 mmHg) to obtain cytological smears and tissue cores; cell blocks are prepared when necessary for immunohistochemistry (IHC) and molecular testing.

Beyond lung cancer staging, EBUS-TBNA needles are vital for diagnosing benign conditions. Confirming sarcoidosis requires sufficient lymphocytic aggregates and non-necrotizing granulomas, often necessitating sampling from ≥3 stations using larger-bore needles (21G or 19G). Tuberculosis diagnosis requires acid-fast staining and culture, demanding samples containing necrotic material or viable tissue. Suspected lymphoma strongly favors Fine Needle Biopsy (FNB)-type needles to procure tissue cores rather than mere cytology specimens. Notably, access to subaortic (stations 5 and 6) lymph nodes is limited by aortic interference and angulation constraints; combining EBUS-TBNA with Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) provides complementary coverage. Regarding re-staging, post-neoadjuvant chemotherapy mediastinal reassessment via EBUS-TBNA is feasible, but false negatives due to fibrosis necessitate surgical confirmation if results are negative.

In summary, the EBUS-TBNA needle has evolved from a simple "sampling tool" into a critical medical device influencing the entire lung cancer management continuum-initial diagnosis, staging, re-staging, and treatment response evaluation. Its clinical efficacy is closely tied to needle selection (gauge, tip design, material), operator expertise, and integration with Rapid On-Site Evaluation (ROSE), making it a high-interest topic in respiratory interventional equipment configuration and procedural standardization.